Concepedia

Nobuya Ishii

NI

33

Publications

2.6K

Citations

22

H-Index

1991

Active since

Affiliations

Chugai Pharma (United States)(Current)

Memorial Sloan Kettering Cancer Center

Dana-Farber Cancer Institute

The University of Texas MD Anderson Cancer Center

Massachusetts General Hospital

Nobuya Ishii is an author at Chugai Pharma (United States) specializing in medicine, tumor biology, and cell biology.

Top concepts

MedicineTumor BiologyCell BiologyOncologyPharmacologyCancer BiologyCancer ResearchRadiation OncologyTumor MicroenvironmentPathology

Publications per year

1991–2019

33

Publications

33

CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant

Hiroshi Sakamoto, Toshiyuki Tsukaguchi, Sayuri Hiroshima et al. · Cancer Cell · 2011 · 618 citations · Full text

Molecular Pharmacology, Resistant Gatekeeper Mutant, Drug Discovery +8

Indoleamine 2,3-Dioxygenase Serves as a Marker of Poor Prognosis in Gene Expression Profiles of Serous Ovarian Cancer Cells

Aikou Okamoto, Takashi Nikaido, Kazunori Ochiai et al. · Clinical Cancer Research · 2005 · 394 citations

Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors

Piro Lito, Anna Saborowski, Jingyin Yue et al. · Cancer Cell · 2014 · 304 citations · Full text

Effective Mek Inhibition, Kras Mutant Tumors, Signaling Pathway +9

Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity

Nobuya Ishii, Naoki Harada, Eric W. Joseph et al. · Cancer Research · 2013 · 160 citations

Raf Feedback Limits, Raf Activity, Cancer Biology +17

Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine

James Nagarajah, Mina Le, Jeffrey A. Knauf et al. · Journal of Clinical Investigation · 2016 · 134 citations · Full text

Engineering, Erk Inhibition, Tumor Biology +20

Rows per page

1–5 of 33